{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:43Z","timestamp":1791607783025,"version":"4.3.4"},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,6]]},"DOI":"10.1248\/bpb.b26-00267","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:11:50Z","timestamp":1791238310000},"page":"1616-1622","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition and Knockdown of Monocarboxylate Transporter 1 Induce L-Lactate Accumulation in T-Cell Acute Lymphoblastic Leukemia Cells"],"prefix":"10.1248","volume":"49","author":[{"given":"Yudai","family":"Suganuma","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Mukai","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinata","family":"Ueda","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Narumi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Halestrap AP, Wilson MC. The monocarboxylate transporter family\u2014role and regulation. <i>IUBMB Life<\/i>, <b>64<\/b>, 109\u2013119 (2012).","DOI":"10.1002\/iub.572"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Fisel P, Schaeffeler E, Schwab M. Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy. <i>Clin. Transl. Sci.<\/i>, <b>11<\/b>, 352\u2013364 (2018).","DOI":"10.1111\/cts.12551"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kobayashi M, Narumi K, Furugen A, Iseki K. Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). <i>Pharmacol. Ther.<\/i>, <b>226<\/b>, 107862 (2021).","DOI":"10.1016\/j.pharmthera.2021.107862"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Yamaguchi A, Narumi K, Furugen A, Iseki K, Kobayashi M. Identification of the essential extracellular aspartic acids conserved in human monocarboxylate transporters 1, 2, and 4. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>529<\/b>, 1061\u20131065 (2020).","DOI":"10.1016\/j.bbrc.2020.06.068"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Futagi Y, Sasaki S, Kobayashi M, Narumi K, Furugen A, Iseki K. The flexible cytoplasmic loop 3 contributes to the substrate affinity of human monocarboxylate transporters. <i>Biochim. Biophys. Acta Biomembr.<\/i>, <b>1859<\/b>, 1790\u20131795 (2017).","DOI":"10.1016\/j.bbamem.2017.05.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sasaki S, Kobayashi M, Futagi Y, Ogura J, Yamaguchi H, Takahashi N, Iseki K. Crucial residue involved in l-lactate recognition by human monocarboxylate transporter 4 (hMCT4). <i>PLOS ONE<\/i>, <b>8<\/b>, e67690 (2013).","DOI":"10.1371\/journal.pone.0067690"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cai X, Ng CP, Jones O, Fung TS, Ryu KW, Li D, Thompson CB. Lactate activates the mitochondrial electron transport chain independently of its metabolism. <i>Mol. Cell<\/i>, <b>83<\/b>, 3904\u20133920.e7 (2023).","DOI":"10.1016\/j.molcel.2023.09.034"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Halestrap AP. The monocarboxylate transporter family\u2014structure and functional characterization. <i>IUBMB Life<\/i>, <b>64<\/b>, 1\u20139 (2012).","DOI":"10.1002\/iub.573"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Payen VL, Mina E, Van H\u00e9e VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. <i>Mol. Metab.<\/i>, <b>33<\/b>, 48\u201366 (2020).","DOI":"10.1016\/j.molmet.2019.07.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mukai Y, Yamaguchi A, Suganuma Y, Okamoto K, Matsumoto N, Narumi K, Kobayashi M. Association between the expression of monocarboxylate transporters in tumors and surrounding stromal cells and cancer prognosis: a meta-analysis. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 1960\u20131971 (2025).","DOI":"10.1248\/bpb.b25-00343"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. <i>Science<\/i>, <b>324<\/b>, 1029\u20131033 (2009).","DOI":"10.1126\/science.1160809"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. <i>J. Exp. Clin. Cancer Res.<\/i>, <b>34<\/b>, 111 (2015). \u2039https:\/\/link.springer.com\/article\/10.1186\/s13046-015-0221-y\u203a.","DOI":"10.1186\/s13046-015-0221-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sasaki S, Futagi Y, Ideno M, Kobayashi M, Narumi K, Furugen A, Iseki K. Effect of diclofenac on SLC16A3\/MCT4 by the Caco-2 cell line. <i>Drug Metab. Pharmacokinet.<\/i>, <b>31<\/b>, 218\u2013223 (2016).","DOI":"10.1016\/j.dmpk.2016.03.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Mukai Y, Yamaguchi A, Sakuma T, Nadai T, Furugen A, Narumi K, Kobayashi M. Involvement of <i>SLC16A1<\/i>\/MCT1 and <i>SLC16A3<\/i>\/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line. <i>Biopharm. Drug Dispos.<\/i>, <b>43<\/b>, 183\u2013191 (2022).","DOI":"10.1002\/bdd.2329"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. <i>Blood Rev.<\/i>, <b>32<\/b>, 36\u201351 (2018).","DOI":"10.1016\/j.blre.2017.08.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cordo\u2019 V, van der Zwet JCG, Cant\u00e9-Barrett K, Pieters R, Meijerink JPP. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies. <i>Blood Cancer Discov.<\/i>, <b>2<\/b>, 19\u201331 (2021).","DOI":"10.1158\/2643-3230.BCD-20-0093"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Altaf E, Huang X, Xiong J, Yang X, Deng X, Xiong M, Zhou L, Pan S, Yuan W, Li X, Hao L, Tembo KM, Xiao R, Zhang Q. NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia. <i>Oncol. Lett.<\/i>, <b>14<\/b>, 4256\u20134262 (2017).","DOI":"10.3892\/ol.2017.6716"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Liu S, Xiang Y, Wang B, Gao C, Chen Z, Xie S, Wu J, Liu Y, Zhao X, Yang C, Yue Z, Wang L, Wen X, Zhang R, Zhang F, Xu H, Zhai X, Zheng H, Zhang H, Qian M. USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia <i>via<\/i> PLK1\/LDHA axis. <i>Blood Adv.<\/i>, <b>7<\/b>, 3099\u20133112 (2023).","DOI":"10.1182\/bloodadvances.2022008284"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Murray CM, Hutchinson R, Bantick JR, <i>et al<\/i>. Monocarboxylate transporter MCT1 is a target for immunosuppression. <i>Nat. Chem. Biol.<\/i>, <b>1<\/b>, 371\u2013376 (2005).","DOI":"10.1038\/nchembio744"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Wang Z, Wang H, Wang Q, Huang T, Guo C, Ji J, Su M, Xu W, Cao Y, Dong Z. Transcriptome analysis of anaerobic glycolysis effects on Jurkat T cell proliferation. <i>Cent. Eur. J. Immunol.<\/i>, <b>49<\/b>, 194\u2013202 (2024).","DOI":"10.5114\/ceji.2024.142116"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7\u201310. <i>Biochem. J.<\/i>, <b>425<\/b>, 523\u2013530 (2010).","DOI":"10.1042\/BJ20091515"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamaguchi A, Mukai Y, Sakuma T, Furugen A, Narumi K, Kobayashi M. Atorvastatin exerts more selective inhibitory effects on hMCT2 than on hMCT1 and hMCT4. <i>Anticancer Res.<\/i>, <b>43<\/b>, 3015\u20133022 (2023).","DOI":"10.21873\/anticanres.16472"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Goldberg FW, Kettle JG, Lamont GM, Buttar D, Ting AKT, McGuire TM, Cook CR, Beattie D, Morentin Gutierrez P, Kavanagh SL, Komen JC, Kawatkar A, Clark R, Hopcroft L, Hughes G, Critchlow SE. Discovery of clinical candidate AZD0095, a selective inhibitor of monocarboxylate transporter 4 (MCT4) for oncology. <i>J. Med. Chem.<\/i>, <b>66<\/b>, 384\u2013397 (2023).","DOI":"10.1021\/acs.jmedchem.2c01342"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Cluntun AA, Badolia R, Lettlova S, <i>et al<\/i>. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. <i>Cell Metab.<\/i>, <b>33<\/b>, 629\u2013648.e10 (2021).","DOI":"10.1016\/j.cmet.2020.12.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sakuma T, Mukai Y, Yamaguchi A, Suganuma Y, Okamoto K, Furugen A, Narumi K, Ishikawa S, Saito Y, Kobayashi M. Monocarboxylate transporters 1 and 2 are responsible for l-lactate uptake in differentiated human neuroblastoma SH-SY5Y cells. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 764\u2013770 (2024).","DOI":"10.1248\/bpb.b23-00860"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). <i>J. Biol. Chem.<\/i>, <b>280<\/b>, 27213\u201327221 (2005).","DOI":"10.1074\/jbc.M411950200"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ng OH, Erbilgin Y, Firtina S, Celkan T, Karakas Z, Aydogan G, Turkkan E, Yildirmak Y, Timur C, Zengin E, van Dongen JJ, Staal FJ, Ozbek U, Sayitoglu M. Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. <i>Blood Cancer J.<\/i>, <b>4<\/b>, e192 (2014).","DOI":"10.1038\/bcj.2014.12"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sipil\u00e4 K, Rognoni E, Jokinen J, Tewary M, Vietri Rudan M, Talvi S, Jokinen V, Dahlstr\u00f6m KM, Liakath-Ali K, Mobasseri A, Du-Harpur X, K\u00e4pyl\u00e4 J, Nutt SL, Salminen TA, Heino J, Watt FM. Embigin is a fibronectin receptor that affects sebaceous gland differentiation and metabolism. <i>Dev. Cell<\/i>, <b>57<\/b>, 1453\u20131465.e7 (2022).","DOI":"10.1016\/j.devcel.2022.05.011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Herranz D, Ambesi-Impiombato A, Sudderth J, S\u00e1nchez-Mart\u00edn M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, M\u00e1rquez J, Mat\u00e9s JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <i>Nat. Med.<\/i>, <b>21<\/b>, 1182\u20131189 (2015).","DOI":"10.1038\/nm.3955"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Liu S, Liao S, Liang L, Deng J, Zhou Y. The relationship between CD4<sup>+<\/sup> T cell glycolysis and their functions. <i>Trends Endocrinol. Metab.<\/i>, <b>34<\/b>, 345\u2013360 (2023).","DOI":"10.1016\/j.tem.2023.03.006"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Gan L, Xiu R, Ren P, Yue M, Su H, Guo G, Xiao D, Yu J, Jiang H, Liu H, Hu G, Qing G. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. <i>Oncogene<\/i>, <b>35<\/b>, 3037\u20133048 (2016).","DOI":"10.1038\/onc.2015.360"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Pola\u0144ski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow CJ. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. <i>Clin. Cancer Res.<\/i>, <b>20<\/b>, 926\u2013937 (2014).","DOI":"10.1158\/1078-0432.CCR-13-2270"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, Chung YL, Eykyn TR, Smith PD, Leach MO. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. <i>Cancer Res.<\/i>, <b>77<\/b>, 5913\u20135924 (2017).","DOI":"10.1158\/0008-5472.CAN-16-2686"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00267\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:20:57Z","timestamp":1791606057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00267\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00267","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"b26-00267"}}